News & Updates

The age of patients with advanced breast cancer appears to have no influence on the rate of palbociclib dose reductions or discontinuations secondary to neutropaenia, a study has shown.

Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Paediatric patients with acute myeloid leukaemia and other leukaemias (AML/OLs), especially those with persistent neutropaenia during the first 30 postoperative days, are at increased risk of early catheter-related bloodstream infections (CRBSIs), according to a Singapore study.

In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.

In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.

In the subgroup analysis of the HERO trial, the first-in-class oral, highly selective, GnRH* antagonist relugolix was effective and well tolerated in Asian men with advanced prostate cancer.